Key facts
- ViTToria Biotherapeutics’s last known valuation is $30.0M (Nov 2024).
- It has raised $49.9M across 1 recorded rounds; the latest was Early Stage VC ($8.7M) in Jul 2021.
- Notable investors include KB Investment, Ben Franklin Technology Partners of Southeastern Pennsylvania, SV Health Investors, BioAdvance Capital (Conshohocken), NYBC Ventures — 15 tracked in total.
- ViTToria Biotherapeutics has filed 1 Form D with the SEC, most recently Dec 2021 ($8.7M sold to 11 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for ViTToria Biotherapeutics
Funding rounds
1 roundsAbout ViTToria Biotherapeutics
Operator of a T-cell therapeutics company intended to offer a therapeutic pipeline targeting clinical needs in oncology and autoimmune disease. The company's technology improves efficacy, enhances safety, and expands the utility of cell-based therapeutics by lowering dosing requirements, easing preconditioning regimens, reducing manufacturing failures, and shortening vein-to-vein times, enabling medical practitioners to improve patient outcomes.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2021
- Employees
- 12
- Website
- vittoriabio.com/
- Ownership
- Privately Held (backing)
ViTToria Biotherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ViTToria Biotherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ViTToria Biotherapeutics in its N-PORT filings yet. We sweep new filings monthly.